Eravacycline Shows Sustained Antimicrobial Activity Against Resistant Bacteria in vitro
Key Insights
Two in vitro studies presented at IDWeek 2024 demonstrate eravacycline's consistent antimicrobial activity against drug-resistant bacteria.
Eravacycline showed high susceptibility (98.13%) against Carbapenem-resistant _Acinetobacter baumannii (search)_ (CRAB (search)) using ChinaCAST breakpoint of 1 µg/mL.
A global study of 23,127 isolates showed eravacycline maintained high susceptibility against major Gram-positive and Gram-negative bacteria from 2018-2022.
Everest Medicines (search) announced new data presented at IDWeek 2024 in Los Angeles, California, highlighting the sustained and robust antimicrobial activity of eravacycline (XERAVA®) against various drug-resistant bacteria. Two in vitro studies demonstrated the drug's potential in combating complicated infections.
Eravacycline's Activity Against Carbapenem-Resistant Acinetobacter baumannii
The first study assessed eravacycline's in vitro antimicrobial activity against 587 strains of Carbapenem-resistant Acinetobacter baumannii (search) (CRAB (search)). Researchers used broth microdilution, MIC test strip (MTS), and disk diffusion methods. Utilizing the ChinaCAST breakpoint of 1 µg/mL, eravacycline exhibited a high susceptibility rate of 98.13% (576/587) via broth microdilution. MTS detected a susceptibility rate of 97.96% (575/587), and disk diffusion showed 97.61% (573/587). The consistency across all three antimicrobial susceptibility test (AST) methods underscored the reliability of eravacycline's susceptibility results in clinical microbiology settings. It is important to note that Xerava® is not indicated for infections caused by Acinetobacter spp. including CRAB, and additional clinical data are necessary to establish efficacy.
Consistent Global Activity Against Major Bacterial Pathogens
The second study evaluated eravacycline's in vitro activity against 23,127 global clinical isolates of major Gram-positive and Gram-negative bacteria, including drug-resistant strains, collected from Asia, Europe, and North America between 2018 and 2022. The results indicated that eravacycline has consistently maintained a high level of susceptibility against clinically relevant pathogens across diverse geographic regions and infection sites since its approval in 2018. This stable in vitro antimicrobial activity supports eravacycline's use in treating complicated intra-abdominal infections caused by both Gram-negative and Gram-positive bacteria.
Executive Insights
Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines (search), stated, "The in vitro study results for eravacycline presented at IDWeek further underscore its broad-spectrum antibacterial coverage and potent activity as the world's first and only new class of antibacterial—fluorocyclines... With the global threat of antimicrobial resistance on the rise, the latest findings on eravacycline are encouraging. We are committed to collaborating with medical experts across specialties to further explore and promote its rational use, ensuring that eravacycline can effectively support more patients affected by complex infections."
Regulatory and Clinical Context
XERAVA® was approved by China's National Medical Products Administration (NMPA) in March 2023 and commercially launched in July 2023. Its antibacterial spectrum covers a wide range of clinically relevant bacteria, including Gram-negative, Gram-positive, and anaerobic bacteria. Eravacycline has been included in several clinical guidelines, such as the 2023 edition of China's "Diagnosis, Treatment, and Prevention Guidelines for Carbapenem-Resistant Gram-Negative Organisms (CRO) Infections."
In March 2024, the World Health Organization (WHO) categorized fluorocycline as a new class of antimicrobial drugs, with eravacycline as the only drug in this class. An interim report from the "Comprehensive Evaluation Project on the Clinical Application of Eravacycline" showed an overall effectiveness of eravacycline at 3 days of treatment was 90.9%, and the overall treatment effectiveness at the end of treatment was 89.0% since its commercialization.